Thus, we have reason to believe that anti-tumor immunity will be more active in the PI3K pathway mutation group after targeting these immunomodulators using ICIs, and reactivated killer immune cells will exert anti-tumor function and improve patient outcomes [50–52]. The gene discussed is PIK3CA; the disease is neoplasm.